LT4780B - Živ proteazės inhibitoriaus rūgštusis sulfatas - Google Patents

Živ proteazės inhibitoriaus rūgštusis sulfatas Download PDF

Info

Publication number
LT4780B
LT4780B LT2000067A LT2000067A LT4780B LT 4780 B LT4780 B LT 4780B LT 2000067 A LT2000067 A LT 2000067A LT 2000067 A LT2000067 A LT 2000067A LT 4780 B LT4780 B LT 4780B
Authority
LT
Lithuania
Prior art keywords
free base
solubility
acid
sulfate
compound
Prior art date
Application number
LT2000067A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000067A (en
Inventor
Janak Singh
Madhusudhan Pudipeddi
Mark D. Lindrud
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4780(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2000067A publication Critical patent/LT2000067A/xx
Publication of LT4780B publication Critical patent/LT4780B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT2000067A 1998-01-20 2000-07-14 Živ proteazės inhibitoriaus rūgštusis sulfatas LT4780B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20

Publications (2)

Publication Number Publication Date
LT2000067A LT2000067A (en) 2000-11-27
LT4780B true LT4780B (lt) 2001-04-25

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000067A LT4780B (lt) 1998-01-20 2000-07-14 Živ proteazės inhibitoriaus rūgštusis sulfatas

Country Status (39)

Country Link
US (1) US6087383A (es)
EP (1) EP1056722B1 (es)
JP (2) JP4860037B2 (es)
KR (1) KR100559283B1 (es)
CN (1) CN1116282C (es)
AR (1) AR014417A1 (es)
AT (1) ATE219057T1 (es)
AU (1) AU735875B2 (es)
BG (1) BG64774B1 (es)
BR (1) BR9814736A (es)
CA (1) CA2317736C (es)
CO (1) CO4970820A1 (es)
CZ (1) CZ293507B6 (es)
DE (1) DE69806067T2 (es)
DK (1) DK1056722T3 (es)
EE (1) EE04434B1 (es)
EG (1) EG23936A (es)
ES (1) ES2178300T3 (es)
GE (1) GEP20033026B (es)
HK (2) HK1033667A1 (es)
HU (1) HU227196B1 (es)
IL (2) IL137384A0 (es)
LT (1) LT4780B (es)
LV (1) LV12522B (es)
MY (1) MY114838A (es)
NO (1) NO315605B1 (es)
NZ (1) NZ504417A (es)
PE (1) PE20000185A1 (es)
PL (1) PL190744B1 (es)
PT (1) PT1056722E (es)
RO (1) RO118869B1 (es)
RU (1) RU2186070C2 (es)
SK (1) SK283975B6 (es)
TR (1) TR200001876T2 (es)
TW (1) TW531531B (es)
UA (1) UA59432C2 (es)
UY (1) UY25345A1 (es)
WO (1) WO1999036404A1 (es)
ZA (1) ZA9956B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004534771A (ja) 2001-05-22 2004-11-18 イーラン　ファーマスーティカルズ、インコーポレイテッド アザヒドロキシル化エチルアミン化合物
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US20040224916A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
CA2657936C (en) * 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir
DE602008005896D1 (de) * 2007-06-22 2011-05-12 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
AU2008268630A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
KR20100028656A (ko) * 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
WO2009136365A1 (en) * 2008-05-08 2009-11-12 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
WO2010079497A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of atazanavir sulfate
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
HRP20211826T1 (hr) 2009-10-26 2022-03-04 Merck Sharp & Dohme Corp. Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
NZ627826A (en) 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
EP2542527A2 (en) 2010-03-01 2013-01-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
US20130203759A1 (en) 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EA201390464A1 (ru) 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US9382207B2 (en) 2012-08-24 2016-07-05 Laurus Labs Private Limited Process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
ZA201401073B (en) 2013-02-12 2015-12-23 Cipla Ltd Process for preparing atazanavir sulphate
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040029A1 (en) 1996-04-22 1997-10-30 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040029A1 (en) 1996-04-22 1997-10-30 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
GEP20033026B (en) 2003-07-25
EE04434B1 (et) 2005-02-15
NO20003692D0 (no) 2000-07-19
CZ20002564A3 (cs) 2000-10-11
CN1283188A (zh) 2001-02-07
ZA9956B (en) 2000-07-05
NO20003692L (no) 2000-07-19
DK1056722T3 (da) 2002-09-30
TW531531B (en) 2003-05-11
NZ504417A (en) 2001-09-28
JP4860037B2 (ja) 2012-01-25
IL137384A0 (en) 2001-07-24
HK1033667A1 (en) 2001-09-14
PE20000185A1 (es) 2000-05-14
EP1056722A1 (en) 2000-12-06
PT1056722E (pt) 2002-09-30
US6087383A (en) 2000-07-11
MY114838A (en) 2003-01-31
EG23936A (en) 2008-01-14
IL137384A (en) 2006-08-01
JP2009102357A (ja) 2009-05-14
PL190744B1 (pl) 2006-01-31
ES2178300T3 (es) 2002-12-16
EP1056722A4 (en) 2001-01-10
TR200001876T2 (tr) 2000-11-21
KR100559283B1 (ko) 2006-03-15
AU735875B2 (en) 2001-07-19
AR014417A1 (es) 2001-02-28
LT2000067A (en) 2000-11-27
EE200000798A (et) 2002-06-17
HK1033458A1 (en) 2001-08-31
UY25345A1 (es) 2000-12-29
SK283975B6 (sk) 2004-06-08
BG104618A (en) 2001-02-28
CO4970820A1 (es) 2000-11-07
JP2002509136A (ja) 2002-03-26
CA2317736C (en) 2004-11-02
SK10622000A3 (sk) 2001-02-12
PL342019A1 (en) 2001-05-07
NO315605B1 (no) 2003-09-29
CA2317736A1 (en) 1999-07-22
HUP0101389A2 (hu) 2001-08-28
DE69806067D1 (de) 2002-07-18
EP1056722B1 (en) 2002-06-12
BR9814736A (pt) 2000-10-24
UA59432C2 (uk) 2003-09-15
ATE219057T1 (de) 2002-06-15
WO1999036404A1 (en) 1999-07-22
LV12522A (en) 2000-08-20
HU227196B1 (en) 2010-10-28
CN1116282C (zh) 2003-07-30
DE69806067T2 (de) 2003-01-23
AU2010199A (en) 1999-08-02
HUP0101389A3 (en) 2003-07-28
CZ293507B6 (cs) 2004-05-12
RO118869B1 (ro) 2003-12-30
LV12522B (en) 2000-10-20
BG64774B1 (bg) 2006-03-31
KR20010034221A (ko) 2001-04-25
RU2186070C2 (ru) 2002-07-27

Similar Documents

Publication Publication Date Title
LT4780B (lt) Živ proteazės inhibitoriaus rūgštusis sulfatas
ES2243553T3 (es) Procedimiento para preparar maleato de amlodipina.
CA2514733A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CS265250B2 (en) Process for preparing anhydrous crystalline natrium salt of 5-chlor-3-/2-thenoyl/-2-oxindol-1-carboxamide
US6828339B2 (en) Amlodipine salt forms and processes for preparing them
WO2023087101A1 (en) Salts of ruxolitinib and crystalline forms thereof
US6737428B2 (en) BIS hydrochloride monohydrate salt of RSV fusion inhibitor
CA3041134A1 (en) Novel salts of nilotinib and crystalline forms thereof
MXPA00006747A (es) Sal de bisulfato del inhibidor de proteasa de vih
SI21703A (en) Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
US7563794B2 (en) Ziprasidone free from colored impurities and a process for its preparation
NL1018758C1 (nl) Aspartaatderivaat van amlodipine.

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

Effective date: 20130926

TC9A Change of representative

Representative=s name: ZABOLIENE, REDA, LT

Effective date: 20130926

MK9A Expiry of a patent

Effective date: 20181222